Century Therapeutics Inc Asset Resilience Ratio
Century Therapeutics Inc asset resilience ratio. Century Therapeutics Inc (IPSC) has an Asset Resilience Ratio of 24.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Century Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Century Therapeutics Inc (2019–2025)
Asset resilience ratio of Century Therapeutics Inc from 2019 to 2025. This chart shows how Century Therapeutics Inc's Asset Resilience Ratio has changed over time. Read IPSC total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Century Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IPSC current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $70.07 Million | 24.41% |
| Total Liquid Assets | $70.07 Million | 24.41% |
Asset Resilience Insights
- Good Liquidity Position: Century Therapeutics Inc maintains a healthy 24.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Century Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Century Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Century Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Century Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Century Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.70% | $55.26 Million | $223.70 Million | -12.34pp |
| 2024-12-31 | 37.05% | $130.85 Million | $353.22 Million | +2.28pp |
| 2023-12-31 | 34.77% | $125.41 Million | $360.69 Million | -12.76pp |
| 2022-12-31 | 47.53% | $231.23 Million | $486.54 Million | +9.47pp |
| 2021-12-31 | 38.05% | $166.43 Million | $437.38 Million | -7.41pp |
| 2020-12-31 | 45.46% | $48.54 Million | $106.78 Million | +4.23pp |
| 2019-12-31 | 41.23% | $37.48 Million | $90.90 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more